Korber A, et al. - Secukinumab, a fully human monoclonal antibody that selectively neutralizes IL-17A, has proven significant efficacy in the treatment of moderate to severe psoriasis. Its efficacy as well safety in elderly subjects was tested in this post-hoc analysis of 3 phase III trials (ERASURE, FIXTURE and CLEAR). Secukinumab was proved to be efficacious and acceptably safe in subjects aged ≥ 65 years with moderate to severe psoriasis, when administered at the recommended dose (300 mg). Furthermore, it showed quality-of-life benefits despite an increased prevalence of cardiovascular and metabolic comorbidities in this population.